Live Breaking News & Updates on James Sapirstein|Page 3

Stay updated with breaking news from James sapirstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First Wave BioPharma (FWBI) Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

First Wave BioPharma (FWBI) Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James Sapirstein , World Health Organization , Drug Administration , First Wave Biopharma Inc , First Wave Biopharma , Proposed Transaction , First Wave ,

First Wave BioPharma Announces Streamlining of Clinical

First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical. ....

Boca Raton , United States , David Schemelia , James Sapirstein , First Wave Biopharma Inc , World Health Organization , Exchange Commission , Drug Administration , Company Annual Report On Form , First Wave Bio Inc , Tiberend Strategic Advisors Inc , Wave Biopharma , Proposed Transaction , First Wave Biopharma , First Wave , First Wave Bio , Annual Report , Strategic Advisors , Nasdaq Fwbi , First Wave Biopharma , Gastrointestinal Diseases , Nai Therapeutics , Inflammatory Bowel Disease , Ulcerative Colitis , Celiac Disease ,

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and AdrulipaseBOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced ....

Boca Raton , United States , James Sapirstein , David Schemelia , World Health Organization , Company Annual Report On Form , First Wave Biopharma Inc , Tiberend Strategic Advisors Inc , Drug Administration , First Wave Bio Inc , Exchange Commission , First Wave Biopharma , Wave Biopharma , Proposed Transaction , First Wave , First Wave Bio , Annual Report , Strategic Advisors , Ulcerative Colitis , Iopharmaceutical Company , Inflammatory Bowel Diseases , Exocrine Pancreatic Insufficiency , Development Pipeline ,

First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline

First Wave BioPharma Inc FWBI has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on… ....

James Sapirstein , Jack Syage , First Wave Biopharma Inc , First Wave Biopharma , Reaking News ,

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal disease clinical pipeline A concurrent institutional. ....

Boca Raton , United States , James Sapirstein , Chaitan Khosla , Jack Syage , David Schemelia , Company Annual Report On Form , Drug Administration , First Wave Biopharma Inc , First Wave Bio Inc , Tungsten Partners , Finalis Securities , Immunogenx Inc , Tiberend Strategic Advisors Inc , Stanford University , Exchange Commission , Gi Division , Globenewswire Inc , First Wave Biopharma , Wave Biopharma , Chief Executive Officer , Chief Operating , First Wave , Wave Bio , Annual Report , Strategic Advisors ,